Kezutin (Piperacillin, Tazobactam)

Kezutin (piperacillin/tazobactam) is used for a range of serious bacterial infections affecting various organ systems.

• Complicated intra‑abdominal infections: delivers broad coverage against aerobic and anaerobic pathogens to resolve infection.
• Complicated urinary tract infections: eradicates resistant Gram‑negative organisms causing pyelonephritis and cystitis.
• Skin and soft tissue infections: treats mixed‑flora infections including MRSA‑susceptible strains.
• Community‑acquired pneumonia: provides empiric therapy against typical and atypical respiratory pathogens.
• Hospital‑acquired pneumonia: targets multidrug‑resistant Gram‑negative bacteria in intensive‑care settings.
• Sepsis: offers rapid bactericidal activity to control systemic infection.

• Piperacillin binds to penicillin‑binding proteins, inhibiting the final step of bacterial cell‑wall peptidoglycan synthesis, which leads to cell lysis. Tazobactam, a β‑lactamase inhibitor, protects piperacillin from enzymatic degradation by many β‑lactamases, thereby extending the antibacterial spectrum to include organisms that would otherwise be resistant.

Adverse reactions may occur with any intravenous antibiotic and should be monitored.

Common Side Effects

• Diarrhea: mild to moderate loose stools.
• Nausea or vomiting: gastrointestinal discomfort.
• Rash or pruritus: mild skin irritation.
• Elevated liver enzymes: transient hepatic enzyme rise.
• Injection site pain: discomfort at the infusion site.
• Mild electrolyte disturbances: occasional changes in sodium or potassium levels.

Serious or Rare Side Effects

• Anaphylaxis: severe allergic reaction requiring immediate medical attention.
• Clostridioides difficile‑associated diarrhea: potentially life‑threatening colitis.
• Severe neutropenia or thrombocytopenia: marked reduction in white blood cells or platelets.
• Stevens‑Johnson syndrome or toxic epidermal necrolysis: severe skin reactions.
• Acute renal impairment: sudden decline in kidney function.
• Hepatotoxicity: significant liver injury.

Careful assessment and monitoring are required before and during therapy.

• Renal function: adjust dosage in patients with impaired kidney function.
• Allergy history: avoid in individuals with known penicillin or β‑lactamase inhibitor hypersensitivity.
• Hepatic function: monitor liver enzymes during prolonged treatment.
• Clostridioides difficile risk: watch for new-onset diarrhea and treat promptly.
• Pregnancy and lactation: use only when the potential benefit justifies the potential risk.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake the solution.

Drug‑drug interactions may alter efficacy or increase toxicity.

Major Interactions (Avoid)

• Probenecid: can increase piperacillin plasma concentrations, raising toxicity risk.
• Methotrexate: reduced clearance may lead to severe myelosuppression.
• Warfarin: potentiates anticoagulant effect, increasing bleeding risk.
• Live vaccines: may diminish vaccine efficacy.
• Aminoglycosides: combined nephrotoxicity.

Moderate Interactions (Monitor Closely)

• Diuretics: may affect electrolyte balance and renal clearance.
• Oral contraceptives: possible reduction in contraceptive effectiveness.
• Vancomycin: additive nephrotoxic potential when used together.